Zhuhai Rundu Pharmaceutical Management
Management criteria checks 4/4
Zhuhai Rundu Pharmaceutical's CEO is Jie Liu, appointed in Oct 2018, has a tenure of 6.17 years. directly owns 0.13% of the company’s shares, worth CN¥4.18M. The average tenure of the management team and the board of directors is 4.6 years and 4.8 years respectively.
Key information
Jie Liu
Chief executive officer
CN¥693.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.6yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Zhuhai Rundu Pharmaceutical's (SZSE:002923) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 04
Zhuhai Rundu Pharmaceutical's (SZSE:002923) Dividend Is Being Reduced To CN¥0.20
May 29There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings
May 05There's Reason For Concern Over Zhuhai Rundu Pharmaceutical Co., Ltd.'s (SZSE:002923) Massive 32% Price Jump
Mar 05CEO
Jie Liu (48 yo)
6.2yrs
Tenure
CN¥693,500
Compensation
Mr. Jie Liu is General Manager of Zhuhai Rundu Pharmaceutical Co., Ltd. since October 21, 2018 and serves as its Director since March 2020. He was Deputy General Manager of Zhuhai Rundu Pharmaceutical Co.,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 6.2yrs | CN¥693.50k | 0.13% CN¥ 4.2m | |
| Deputy GM | 13.7yrs | CN¥572.40k | 0.18% CN¥ 6.0m | |
| Deputy GM & Director | 6.9yrs | CN¥672.70k | 0.12% CN¥ 4.1m | |
| Board Secretary | 2.1yrs | CN¥532.80k | 0.020% CN¥ 654.8k | |
| Deputy General Manager | 3yrs | CN¥553.10k | 0.013% CN¥ 427.5k | |
| Deputy General Manager | 2.1yrs | CN¥532.70k | no data |
4.6yrs
Average Tenure
47yo
Average Age
Experienced Management: 002923's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 4.8yrs | CN¥693.50k | 0.13% CN¥ 4.2m | |
| Deputy GM & Director | 4.8yrs | CN¥672.70k | 0.12% CN¥ 4.1m | |
| Chairman | 6.2yrs | CN¥742.80k | 30.12% CN¥ 1.0b | |
| Independent Director | 5.6yrs | CN¥113.30k | no data | |
| Chairman of the Supervisory Board | 13.7yrs | no data | no data | |
| Supervisor | 6.1yrs | no data | no data | |
| Non-Independent Director | 1.8yrs | CN¥9.00k | no data | |
| Independent Director | 1.8yrs | CN¥88.30k | no data | |
| Independent Director | 1.8yrs | CN¥88.30k | no data |
4.8yrs
Average Tenure
55yo
Average Age
Experienced Board: 002923's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 01:04 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhuhai Rundu Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|